



UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUL 17 2008

The Honorable Carl Levin  
Chairman, Committee on Armed Services  
United States Senate  
Washington, DC 20510-6050

Dear Mr. Chairman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DOD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.


The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package).

Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink, appearing to read "David S. C. Chu". The signature is fluid and cursive, with a large initial "D" and "C".

David S. C. Chu

cc:

The Honorable John McCain  
Ranking Member



UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUN 17 2008

The Honorable Ben Nelson  
Chairman, Subcommittee on Personnel  
Committee on Armed Services  
United States Senate  
Washington, DC 20510-6050

Dear Mr. Chairman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DoD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.

The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are

approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package). Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink that reads "David S. C. Chu". The signature is written in a cursive style with a large, looping initial "D".

David S. C. Chu

cc:  
The Honorable Lindsey O. Graham  
Ranking Member



UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUN 17 2008

The Honorable Ike Skelton  
Chairman, Committee on Armed Services  
U.S. House of Representatives  
Washington, DC 20515-6035

Dear Mr. Chairman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DoD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.


The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package).

Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink, appearing to read "David S. C. Chu". The signature is written in a cursive style with a large, looping initial "D".

David S. C. Chu

cc:

The Honorable Duncan Hunter  
Ranking Member



UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUN 17 2008

The Honorable Susan Davis  
Chairwoman, Subcommittee on Military Personnel  
Committee on Armed Services  
U.S. House of Representatives  
Washington, DC 20515-6035

Dear Madam Chairwoman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DoD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.


The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are

approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package). Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink, appearing to read "David S. C. Chu". The signature is written in a cursive style with a large, looping initial "D".

David S. C. Chu

cc:

The Honorable John M. McHugh  
Ranking Member





UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUN 17 2008

The Honorable Robert C. Byrd  
Chairman, Committee on Appropriations  
United States Senate  
Washington, DC 20510-6025

Dear Mr. Chairman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DoD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.


The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package).

Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink, appearing to read "David S. C. Chu". The signature is written in a cursive style with a large, looping initial "D".

David S. C. Chu

cc:  
The Honorable Thad Cochran  
Ranking Member



UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUN 17 2008

The Honorable Daniel K. Inouye  
Chairman, Subcommittee on Defense  
Committee on Appropriations  
United States Senate  
Washington, DC 20510-6028

Dear Mr. Chairman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DoD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.


The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are

approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package). Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink, appearing to read "David S. C. Chu". The signature is fluid and cursive, with a large initial "D" and a long, sweeping underline.

David S. C. Chu

cc:  
The Honorable Ted Stevens  
Ranking Member



UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUN 17 2008

The Honorable David R. Obey  
Chairman, Committee on Appropriations  
U.S. House of Representatives  
Washington, DC 20515-6015

Dear Mr. Chairman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DoD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.


The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package).

Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink, appearing to read "David S. C. Chu". The signature is fluid and cursive, with a large initial "D" and a long horizontal stroke at the end.

David S. C. Chu

cc:  
The Honorable Jerry Lewis  
Ranking Member



UNDER SECRETARY OF DEFENSE  
4000 DEFENSE PENTAGON  
WASHINGTON, D.C. 20301-4000

PERSONNEL AND  
READINESS

JUN 17 2008

The Honorable John P. Murtha  
Chairman, Subcommittee on Defense  
Committee on Appropriations  
U.S. House of Representatives  
Washington, DC 20515-6018

Dear Mr. Chairman:

I am responding to the Department of Defense (DoD) Appropriations for Fiscal Year 2008 Conference Report 110-434 that requests a report on the current policies for maintaining the Japanese encephalitis vaccine (JEV) stockpile, the status of replacing the current JEV, and the costs associated with such a replacement.

DoD has created forward-located stockpiles of certain drugs (mostly the anti-virals used to treat avian influenza) because there is a documented clinical requirement to treat people with these drugs within hours of exhibiting symptoms. We also have stockpiled certain items facing a gap in availability, which is the case with JEV. We normally do not stockpile products for use in responding to contingencies when we can acquire adequate supplies via contract. This strategy is the basis for the Defense Supply Center, Philadelphia's (DSCP) Contingency Contracts Program that has been validated both economically and operationally.


The current JEV stockpile owes its existence to a unique set of circumstances. It was established because the former supplier was stopping production, and the stockpile was the only way to assure continuity of supply until a new source would be available. A new manufacturer submitted a licensure application to the U.S. Food and Drug Administration on December 20, 2007, and expects approval in late fiscal year 2008. We do not intend to maintain the JEV stockpile once the new source is available. DSCP intends to exhaust the existing stockpile, and then procure the new vaccine. Because of the limited shelf life of vaccines and the costs of storage and maintenance of a stockpile, the optimal logistical plan is to contract for vaccine that will meet ongoing needs rather than to obtain and maintain a stockpile.

The currently approved JEV was purchased from unit operating funds, principally by U.S. Marine Corps units for Service members in areas of Asia considered at risk. The vaccine also was purchased, as required, by military medical treatment facilities. We have not captured specific unit expenditures, but total DoD expenditures for JEV are

approximately \$3 million per year (2,700 packages/month, 12 months/year, \$90/package). Despite repeated requests, the manufacturer of the new vaccine has not provided the cost per dose. Consequently, costs for replacement of JEV cannot be described with accuracy at this time.

Thank you for your continued support to the Military Health System.

Sincerely,

A handwritten signature in black ink, appearing to read "David S. C. Chu". The signature is fluid and cursive, with a large initial "D" and a long horizontal stroke at the end.

David S. C. Chu

cc:  
The Honorable C. W. Bill Young  
Ranking Member



**Appropriations Conference Report**

**110-434 p. 358**

**REPLACEMENT OF JAPANESE ENCEPHALITIS VACCINE**

The conferees direct the Undersecretary of Defense for Personnel and Readiness to report to the Congressional Defense committees by April 15, 2008, on the current policies for maintaining the Japanese encephalitis vaccine stockpile, the status of replacing the current Japanese encephalitis virus vaccine, and the costs associated with such a replacement.